Baber U, Spirito A, Sartori S, Angiolillo DJ, Briguori C, Cohen DJ, et al
Damluji, MD, PhD, MBA Published Mar 29, 2025 The SOUL trial, published in The New England Journal of Medicine on March 29, 2025, provides new evidence that once-daily oral semaglutide reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes and a history of atherosclerotic cardiovascular disease, chronic kidney disease, or both
Throughout the episode, I explain the science and key mechanisms underlying romantic love and outline tools for those seeking to find a strong, healthy relationship, or for those wanting to strengthen an existing relationship
No matter how you connect with us, our team is dedicated to guiding you on your weight loss journey every step of the way
Reductions in joint pain and stiffness typically develop within 24 to 72 hours as systemic inflammation levels decrease